Lucintel’s latest market report analyzed that liquid biopsy provides attractive opportunities in reference laboratories, hospitals and physician laboratories, and academic and research centers. The liquid biopsy market is expected to reach $10.4 billion by 2027 with a CAGR of 17%. In this market, circulating tumor DNA (ctDNA) is the largest segment by circulating biomarker, whereas therapy selection is the largest segment by clinical application. The usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector provides strategic growth path in this market.

Download Brochure of this report by clicking on https://www.lucintel.com/liquid-biopsy-market.aspx

Based on circulating biomarker, the liquid biopsy market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers. Lucintel forecasts that the circulating tumor DNA (ctDNA) market accounted for the largest share of the market in 2020 and is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in early stage.     

Browse in-depth TOC on “Liquid Biopsy Market”

129 – Tables

163 – Figures

264 – Pages

The liquid biopsy market is marked by the presence of several big and small players. Some of the prominent players offering liquid biopsy include Guardant, Bio-Rad Laboratories, Qaigen, MDxHealth, Myriad Genetics, Biocept, Roche, Illumina, and Thermofisher.  

Request Sample Report:

https://www.lucintel.com/liquid-biopsy-market.aspx

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link [email protected].

About Lucintel

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

Brandon Fitzgerald
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. 972.636.5056
Cell: 303.775.0751

Related reports

Digital Fitness Market:

For more details click here https://www.lucintel.com/roofing-material-market.aspx

Medical Device Market:

For more details click here https://www.lucintel.com/medical-device-market.aspx

3D Printing Medical Device Market:

For more details click here https://www.lucintel.com/3d-printing-medical-device-market.aspx

Medical Lifting Sling Market:

For more details click here https://www.lucintel.com/medical-lifting-sling-market.aspx

Connected Health Device Market:

For more details click here https://www.lucintel.com/connected-health-device-market.aspx

Diagnostic Imaging Market:

For more details click here https://www.lucintel.com/diagnostic-imaging-market.aspx

Global Medical Battery Market:

For more details click here https://www.lucintel.com/medical-battery-market.aspx

Interventional Cardiology and Peripheral Vascular Device Market:

For more details click here https://www.lucintel.com/interventional-cardiology-peripheral-vascular-devi.aspx

 

Wheelchair Market Trends:

For more details click here https://www.lucintel.com/wheelchair-market.aspx

  

Coronary Stent Market:

For more details click here https://www.lucintel.com/stents-market.aspx

Tags: , , ,

See Campaign: https://www.lucintel.com/liquid-biopsy-market.aspx

Contact Information:

Brandon Fitzgerald Lucintel Dallas, Texas, USA Email: [email protected] Tel. 972.636.5056 Cell: 303.775.0751

Tags:
Financial Content, Reportedtimes, iCN Internal Distribution, Extended Distribution, Research Newswire, English